Amelioration of white-matter lesions in a patient with Fabry disease

Journal of the Neurological Sciences

Volumn 279, Issue 1-2, 2009, Pages 118-120

  Yamadera, M ^a   Yokoe, M ^a   Beck, G ^a   Mihara, M ^a   Oe, H ^a   Yamamoto, Y ^a   Sakoda, S ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

galactosidase A; Enzyme replacement therapy; Fabry disease; Inherited metabolic disease; White matter lesion

Indexed keywords

ALPHA GALACTOSIDASE BETA; GLYCOSIDASE; NUCLEOTIDE; UNCLASSIFIED DRUG;

ADULT; ANAMNESIS; ARTICLE; BRAIN DAMAGE; CASE REPORT; CELL COUNT; CEREBROSPINAL FLUID; CLINICAL FEATURE; ENZYME REPLACEMENT; EXON; FABRY DISEASE; GENE DELETION; GENE MUTATION; HUMAN; LABORATORY TEST; MALE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; WHITE MATTER;

ADULT; ALPHA-GALACTOSIDASE; BRAIN; FABRY DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NERVE FIBERS, MYELINATED; SEQUENCE DELETION; TREATMENT OUTCOME;

EID: 60949103262     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.12.028     Document Type: Article

References (12)

1. Fellgiebel A., Muller M.J., and Ginsberg L. CNS manifestations of Fabry's disease. Lancet Neurol 5 (2006) 791-795
2. Rolfs A., Bottcher T., Zschiesche M., Morris P., Winchester B., Bauer P., et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366 (2005) 1794-1796
3. Moore D.F., Altarescu G., Herscovitch P., and Schiffmann R. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol 2 (2002) 4
4. Crutchfield K.E., Patronas N.J., Dambrosia J.M., Frei K.P., Banerjee T.K., Barton N.W., et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 50 (1998) 1746-1749
5. Callegaro D., and Kaimen-Maciel D.R. Fabry's disease as a differential diagnosis of MS. Int MS J 13 (2006) 27-30
6. Cabrera-Salazar M.A., O'Rourke E., Charria-Ortiz G., and Barranger J.A. Radiological evidence of early cerebral microvascular disease in young children with Fabry disease. J Pediatr 147 (2005) 102-105
7. Jardim L.B., Aesse F., Vedolin L.M., Pitta-Pinheiro C., Marconato J., Burin M.G., et al. White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up. Arq Neuro-Psiquiatr 64 (2006) 711-717
8. Moore D.F., Altarescu G., Barker W.C., Patronas N.J., Herscovitch P., and Schiffmann R. White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 62 (2003) 231-240
9. Moore D.F., Altarescu G., Ling G.S., Jeffries N., Frei K.P., Weibel T., et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 33 (2002) 525-531
10. Moore D.F., Scott L.T., Gladwin M.T., Altarescu G., Kaneski C., Suzuki K., et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104 (2001) 1506-1512
11. Mitsias P., and Levine S.R. Cerebrovascular complications of Fabry's disease. Ann Neurol 40 (1996) 8-17
12. Lidove O., Joly D., Barbey F., Bekri S., Alexandra J.F., Peigne V., et al. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract 61 (2007) 293-302